c(alpha)-formylglycine has been researched along with Mucopolysaccharidosis II in 1 studies
*Mucopolysaccharidosis II: Systemic lysosomal storage disease marked by progressive physical deterioration and caused by a deficiency of L-sulfoiduronate sulfatase. This disease differs from MUCOPOLYSACCHARIDOSIS I by slower progression, lack of corneal clouding, and X-linked rather than autosomal recessive inheritance. The mild form produces near-normal intelligence and life span. The severe form usually causes death by age 15. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MS; Chung, YK; Jin, DK; Kim, CH; Ko, AR; Kwun, Y; Lee, J; Lee, JY; Sohn, JM; Sohn, YB; Yook, YJ | 1 |
1 other study(ies) available for c(alpha)-formylglycine and Mucopolysaccharidosis II
| Article | Year |
|---|---|
A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.
Topics: Alanine; Animals; CHO Cells; Cricetinae; Cricetulus; Enzyme Replacement Therapy; Fibroblasts; Glycine; Humans; Iduronate Sulfatase; Mannosephosphates; Mucopolysaccharidosis II; N-Acetylneuraminic Acid; Recombinant Fusion Proteins | 2014 |